Tumor Necrosis Factor Inhibitors
No difference in outcomes for interleukin-6, TNF inhibitors among RA patients
Rate of major cardiovascular events in RA higher for tofacitinib vs. TNF inhibitors
Tofacitinib is associated with a numerically higher incidence of major adverse cardiac events, versus TNF inhibitors, in patients with rheumatoid arthritis at an increased cardiac risk, according to data presented at ACR Convergence 2021.
Serious infection risk with TNF inhibitors ‘significantly lower’ in PsA vs. RA
Among patients treated with TNF inhibitors, the risk for serious infection was “significantly lower” in those with psoriatic arthritis compared with rheumatoid arthritis, according to data published in the Annals of the Rheumatic Diseases.
Top in rheumatology: Varicella-zoster vaccine and TNF inhibitors, statin use and RA risk
New data showed that the live attenuated varicella-zoster vaccine was safe and provided short-term effectiveness in patients receiving TNF inhibitors. A report on the data was the top story in rheumatology last week.
Live varicella-zoster vaccine effective, 'can be safely used' with TNF inhibitors
The live attenuated varicella-zoster vaccine is safe and provides “reasonable short-term” effectiveness in patients receiving TNF inhibitors for a variety of indications, according to data published in the Annals of Internal Medicine.
VIDEO: Benefit of switching JAK inhibitors before trying injectable, infusion therapy
